TP53 and embryonal rhabdomyosarcoma: Children with embryonal rhabdomyosarcoma and a CPV had outcomes comparable to children with fusion-positive rhabdomyosarcoma, a more aggressive rhabdomyosarcoma subtype, and those with TP53 CPVs had poor outcomes independent of a second malignant neoplasm.